Patrícia De Fátima Dos Santos Teixeira

Prof. Patrícia De Fátima Dos Santos Teixeira


Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Therapeutic Advances in Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
PTPatrícia De Fátima Dos Santos Teixeira
Patrícia De Fátima Dos Santos Teixeira
PSPatrícia Borges dos Santos
Patrícia Borges dos Santos
CPCarmen Cabanelas Pazos-Moura
Carmen Cabanelas Pazos-Moura
Metabolic syndrome (MetS) and thyroid dysfunction are common in clinical practice. The objectives of this review are to discuss some proposed mechanisms by which thyroid dysfunctions may lead to MetS, to describe the bidirectional relationship between thyroid hormones (THs) and adiposity and finally, to resume a list of recent studies in humans that evaluated possible associations between thyroid hormone status and MetS or its clinical components. Not solely THs, but also its metabolites regulate metabolic rate, influencing adiposity. The mechanisms enrolled are related to its direct effect on adenosine triphosphate (ATP) utilization, uncoupling synthesis of ATP, mitochondrial biogenesis, and its inotropic and chronotropic effects. THs also act controlling core body temperature, appetite, and sympathetic activity. In a bidirectional way, thyroid function is affected by adiposity. Leptin is one of the hallmarks, but the pro-inflammatory cytokines and also insulin resistance impact thyroid function and perhaps its structure. MetS development and weight gain have been positively associated with thyroid-stimulating hormone (TSH) in several studies. Adverse glucose metabolism may be related to hyperthyroidism, but also to reduction of thyroid function or higher serum TSH, as do abnormal serum triglyceride levels. Hypo- and hyperthyroidism have been related to higher blood pressure (BP), that may be consequence of genomic or nongenomic action of THs on the vasculature and in the heart. In summary, the interaction between THs and components of MetS is complex and not fully understood. More longitudinal studies controlling each of all confounding variables that interact with endpoints or exposure factors are still necessary.

1 April 2008 in Translational Research
Verified
Journal Article
Closed access
PTPatrícia De Fátima Dos Santos Teixeira
Patrícia De Fátima Dos Santos Teixeira
VRVaneska Spinelli Reuters
Vaneska Spinelli Reuters
MFMárcia Martins Ferreira
Márcia Martins Ferreira
CACloyra Paiva Almeida
Cloyra Paiva Almeida
FRFabíola Alves Aarão Reis
Fabíola Alves Aarão Reis
MVMário Vaisman
Mário Vaisman

18 December 2007 in Hormone and Metabolic Research
Verified
Journal Article
Closed access
PDF file
PTPatrícia De Fátima Dos Santos Teixeira
Patrícia De Fátima Dos Santos Teixeira
VRV. Reuters
V. Reuters
MFM. Ferreira
M. Ferreira
CAC. Almeida
C. Almeida
FRF. Reis
F. Reis
MVM. Vaisman
M. Vaisman
Many studies have found clinical and metabolic alterations in subclinical hypothyroidism, however, there are disagreements about the benefits of levothyroxine therapy. The objective of the present study was to analyze the effects of 6 months of treatment on the lipid profile of patients with subclinical hypothyroidism. A randomized double blind, placebo-controlled clinical assay was conducted. Sixty patients were enrolled in stratified random allocation by TSH levels that generated similar groups in average: free thyroxine levels, lipid levels, age, clinical score, and sedentary. At 6 months, 18 patients in the levothyroxine and 20 in the placebo group were reevaluated and a fall in all atherogenic lipid variables was observed with treatment. The TC and LDL-c variations (-22.6±37.2 and -18.5±34.6 mg/dl, respectively) in the group that received LT4 were statistically different (p=0.023 and p=0.012) from those occurring in the placebo group (+7.3±37.1 and +14.7±40.6 mg/dl). Baseline characteristics associated with better improvement in the levels of TC and LDL-c were the presence of TPO-Ab, TSH levels >8.0 μUI/ml, Body Mass Index ≥25 kg/m2, and the presence of menopause. We concluded that treatment with dose-adjusted levothyroxine reduced atherogenic lipid levels in some patients. Further studies to determine the effects of LT4 replacement in specific subgroups of SH patients are still necessary, especially in patients with TSH <8.0 μUI/ml.

7 December 2020 in Thyroid®
Verified
Journal Article
Closed access
NMNathalie Silva de Morais
Nathalie Silva de Morais
DSDébora Ayres Saraiva
Débora Ayres Saraiva
CCCarolina Corcino
Carolina Corcino
TBTatiana Berbara
Tatiana Berbara
ASAnnie Schtscherbyna
Annie Schtscherbyna
PTPatrícia De Fátima Dos Santos Teixeira
Patrícia De Fátima Dos Santos Teixeira
Background: Insufficient or excessive iodine intake during gestation may compromise adaptive mechanisms in maternal thyroid function and lead to adverse pregnancy outcomes. In this context, we aimed to study the effects of maternal iodine status in the first and third trimesters of gestation on obstetric and neonatal outcomes in an iodine-sufficient population in Rio de Janeiro, Brazil. Methods: A total of 214 pregnant women in the first trimester of gestation were enrolled and prospectively followed until delivery between 2014 and 2017. All participants were ≥18 and ≤35 years, had a spontaneous single pregnancy, and had no history of thyroid or other chronic diseases, nor were they taking iodine-containing supplements at enrollment. In the first trimester, we obtained clinical information and determined thyroid function and the urinary iodine concentration (UIC) of the participants. Thyroid function and UIC were reassessed in the third trimester. Iodine status was determined by the median of UIC obtained from six urine spot samples by the inductively coupled plasma mass spectrometry method. Pregnancy and neonatal outcomes and delivery information were obtained from medical records. Results: The median UIC in the whole population was 219.7 μg/L. The prevalence of UIC <150 μg/L was 17.2%, and 38.7% had UIC ≥250 μg/L. Gestational diabetes (GDM) was higher in the group with UIC 250–499 μg/L ( n = 77) compared with the group with UIC 150–249 μg/L ( n = 94) (20.3% vs. 9.7%, p < 0.05). Ultimately, UIC ≥250 μg/L was an independent risk factors for GDM (relative risk [RR] = 2.9 [confidence interval, CI = 1.1–7.46], p = 0.027) and hypertensive disorders of pregnancy (HDP) (RR = 4.6 [CI = 1.1–18.0], p = 0.029). Among 196 live-born newborns, lower birth length was observed in infants whose mothers had UIC <150μg/L ( n = 37) in the first trimester compared with those with UIC 150–249 μg/L ( n = 86) (median interquartile range: 48.0 [2.2] vs. 49.0 [4.0] cm, p = 0.01). Maternal UIC <150 μg/L was negatively associated with birth length of newborns (Exp (B) = 0.33 [CI = 0.1–0.9], p = 0.03). Conclusions: In a population whose median iodine intake is sufficient, extensive individual variation occurs. Such abnormalities are associated with increased GDM and HDP when UIC is ≥250 μg/L, and lower infant birth length when UIC is <150 μg/L.

1 May 2009 in Thyroid®
Verified
Journal Article
Closed access
PTPatrícia De Fátima Dos Santos Teixeira
Patrícia De Fátima Dos Santos Teixeira
MCMônica D. Cabral
Mônica D. Cabral
NSNathalie A. Silva
Nathalie A. Silva
DSDébora V. Soares
Débora V. Soares
VBValéria B. Braulio
Valéria B. Braulio
MVMário Vaisman
Mário Vaisman
Background: The relationship between thyroid status, including subclinical hypothyroidism (SH) and serum leptin is controversial or uncertain. Therefore we evaluated serum leptin in SH and overt hypothyroidism (OH) and determined the effects of levothyroxine (LT 4 ) replacement on serum leptin in these disorders. Methods: Serum leptin, thyrotropin (TSH), free thyroxine, insulin, glucose, and body composition parameters were compared in 55 SH, 20 OH, and 28 euthyroid (EU) pre- and postmenopausal women. In addition, the effect of LT 4 treatment on serum leptin in SH and OH was assessed. Results: The mean ± SD (median) serum leptin concentrations in the OH and SH groups were higher than in the EU group (35.1 ± 27.2 [33.0] and 36.6 ± 21.9 [30.6] ng/mL, respectively, vs. 23.2 ± 19.3 [17.9] ng/mL, p = 0.011), but the difference was only significant in postmenopausal women. The body mass index (BMI), fat mass index (FMI), and the homeostasis model assessment–insulin resistance (HOMA-IR) index values were not different among these groups. In premenopausal women there was no correlation between leptin, BMI, or FMI and serum TSH levels ( r s = 0.009, p = 0.474; r s = 0.043, p = 0.367; r s = 0.092, p = 0.232). In the postmenopausal women, the partial correlation coefficient between TSH and leptin was present, even when controlling for BMI ( r s = 0.297, p = 0.042) and FMI ( r s = 0.275, p = 0.050). LT 4 treatment was associated with a reduction of serum leptin concentrations in the OH group ( p = 0.008). In SH group there were no differences between LT 4 replacement or no treatment, since a fall in serum leptin levels was detected in both SH subgroups, despite a more pronounced fall with LT 4 use. Treatment of the SH and OH groups with LT 4 did not influence HOMA-IR index or body composition. Conclusions: Serum leptin concentrations are elevated in postmenopausal women with SH or OH. A relationship between thyroid status and serum leptin is further supported by the fact that LT 4 treatment, to restore the EU status, reduced serum leptin levels in OH in the absence of significant effects on BMI. In women, hypothyroidism influences either leptin secretion or degradation and this effect is more pronounced in postmenopausal than in premenopausal women.

8 June 2021 in Thyroid®
Verified
Journal Article
Closed access
AAAline Machado Larcher de Almeida
Aline Machado Larcher de Almeida
RDRicardo Luiz Costantin Delfim
Ricardo Luiz Costantin Delfim
AVAna Paula Aguiar Vidal
Ana Paula Aguiar Vidal
MCMaria Clara D'ARaujo Couto Martins Chaves
Maria Clara D'ARaujo Couto Martins Chaves
ASAna Carolina Lopes Santiago
Ana Carolina Lopes Santiago
PTPatrícia De Fátima Dos Santos Teixeira
Patrícia De Fátima Dos Santos Teixeira
Background: The risk of malignancy (RoM) of indeterminate thyroid nodules (ITNs) shows a high variability in interinstitutional cohorts. The RoM is partially associated with the cytological degree of atypia and the ultrasound (US) pattern. This study evaluated the cancer risk of ITNs by jointly considering the cytological subcategory and the American Thyroid Association (ATA)-based US risk classification. Methods: This study features a retrospective cohort from two Brazilian centers comprising 238 ITNs with confirmed outcomes. US classification, according to ATA-based guidelines, and cytological subcategorization were determined. The cytological subgroups were as follows: (1) nuclear atypia (NA) related to papillary thyroid carcinoma (PTC) but insufficient to categorize the cytology as suspicious for malignancy; (2) architectural atypia without NA (AA); (3) both architectural and nuclear atypia (ANA); (4) oncocytic pattern (OP) without NA; and (5) NA not related to PTC (NANP). NA was divided into three subgroups: nuclear size and shape, nuclear membrane appearance, and/or chromatin aspects. Results: The overall frequency of malignancy was 39.5%. Among the cytological subcategories, the highest RoM was related to the NA (43.9%) and to the ANA (43.5%), followed by AA (29.4%), and OP (9.4%). NA was positively and independently associated with cancer (odds ratio [OR]: 4.5; confidence interval [CI: 1.2–16.6]) as was the occurrence of ANA (OR 6.6 [CI 1.5–29.5]). AA and OP were not independently associated with cancer. Both ATA-based high- and intermediate-risk categories showed an independent association with cancer (OR 6.8 [CI 2.9–15.5] and OR: 2.6 [CI 1.1–5.8], respectively). ITNs with cytological findings of NA or ANA when combined with intermediate US patterns had RoM values of 47.5% and 56.7%, respectively. Both cytological subcategories, when combined with the ATA high-suspicion class reached an RoM >70%. The type of NA with the highest odds for cancer was related to the nuclear membrane (OR 11.5). Conclusions: The RoM of ITNs can reach almost 80% when both NA and ATA-based high-risk US features are present. The presence of such cytological features also increased the RoM in the ATA-based intermediate-risk US category. In addition, AA and OP were not independently related to higher cancer risk. These results strengthen the recommendations for combing cytological subcategorization and US risk classification in the workup for ITNs before the decision of a molecular testing, clinical observation, or diagnostic surgery.